{
    "nct_id": "NCT02344355",
    "official_title": "Pharmacological Ascorbate Combined With Radiation and Temozolomide in Glioblastoma Multiforme: A Phase 2 Trial",
    "inclusion_criteria": "* Ability to understand and willingness to sign informed consent (power of attorney and/or legally authorized representatives cannot sign on behalf of the patient)\n* Patients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiforme.\n* Diagnosis must be made by surgical biopsy or excision.\n* Therapy must begin ≤ 5 weeks after surgery or biopsy\n* Age ≥ 18 years\n* ECOG performance status 0-2. (KPS > 50)\n* Absolute neutrophil count (ANC) ≥ 1500 cells per mm3\n* Platelets ≥ 100,000 per mm3\n* Hemoglobin ≥ 8 g/dL\n* Creatinine ≤ 2.0 mg\n* Total bilirubin ≤ 1.5 mg/dL\n* ALT ≤ 3 times the institutional upper limit of normal\n* AST ≤ 3 times the institutional upper limit of normal\n* Tolerate one test dose (15g) of ascorbate.\n* Not pregnant.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Recurrent high grade glioma\n* G6PD (glucose-6-phosphate dehydrogenase) deficiency.\n* Patients actively receiving insulin or using a finger-stick glucometer daily for blood glucose measurements\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide.\n* Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis.\n* Patients who are on the following drugs and cannot have a drug substitution: warfarin, flecainide, methadone, amphetamines, quinidine, and chlorpropamide.\n* Known active concurrent malignancy, as determined by treating physicians.\n* Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma.\n* Prior radiation therapy to the head or neck resulting in overlap of RT fields.\n* Patients receiving any other investigational agents (imaging agents are acceptable)\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection that would result in a hospital stay or delay of treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or impact patient safety.\n* Pregnant women.\n* Breastfeeding women.\n* Known HIV-positive individuals. High-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs.",
    "miscellaneous_criteria": ""
}